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Some technologies save lives — new vaccines, new surgical techniques, safer highways. Others threaten
lives — pollution, nuclear accidents, global warming, the rapid global transmission of disease, and
bioengineered viruses. How is growth theory altered when technologies involve life and death instead
of just higher consumption? This paper shows that taking life into account has first-order consequences.
Under standard preferences, the value of life may rise faster than consumption, leading society to value
safety over consumption growth. As a result, the optimal rate of consumption growth may be substantially
lower than what is feasible, in some cases falling all the way to zero.
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Certain events quite within the realm of possibility, such as a major as-
teroid collision, global bioterrorism, abrupt global warming — even cer-
tain lab accidents— could have unimaginably terrible consequences up
to and including the extinction of the human race... I am not a Green,
an alarmist, an apocalyptic visionary, a catastrophist, a Chicken Little,
a Luddite, an anticapitalist, or even a pessimist. But... I have come to
believe that what I shall be calling the “catastrophic risks” are real and
growing...
— Richard A. Posner (2004, p. v)
1. Introduction
InOctober 1962, the Cuban missilecrisis brought theworld to thebrink ofanuclear
holocaust. President John F. Kennedy put the chance of nuclear war at “somewhere
betweenoneoutofthreeandeven.” ThehistorianArthurSchlesinger,Jr.,atthetime
anadviserofthe President, latercalledthis “the mostdangerous momentin human
history.”1 What if a substantial fraction of the world’s population had been killed in
a nuclear holocaust in the 1960s? In some sense, the overall cost of the technologi-
cal innovations of the preceding 30 years would then seem to have outweighed the
beneﬁts.
While nuclear devastation represents a vivid example of the potential costs of
technological change, it is by no means unique. The beneﬁts from the internal
combustion engine must be weighed against the costs associated with pollution
and global warming. Biomedical advances have improved health substantially but
made possible weaponized anthrax and lab-enhanced viruses. The potential bene-
ﬁts of nanotechnology stand beside the threat that a self-replicating machine could
someday spin out of control. Experimental physics has brought us x-ray lithogra-
phy techniques and superconductor technologies but also the remote possibility of
devastating accidents as we smashparticles together at ever higher energies. These
1For these quotations, see (Rees, 2003, p. 26).LIFE AND GROWTH 3
andother technological dangers aredetailedinasmallbutgrowing literature onso-
called“existentialrisks”;Posner(2004) islikelythe mostfamiliarofthesereferences,
but see also Bostrom (2002), Joy (2000), Overbye (2008), and Rees (2003).
Technologies need not pose risks to the existence of humanity in order to have
costs worth considering. New technologies come with risks as well as beneﬁts.
A new pesticide may turn out to be harmful to children. New drugs may have
unforeseen side effects. Marie Curie’s discovery of the new element radium led
to many uses of the glow-in-the-dark material, including a medicinal additive to
drinks and baths for supposed health beneﬁts, wristwatches with luminous dials,
and as makeup — at least until the dire health consequences of radioactivity were
better understood. Other examples of new products that were intially thought to be
safe or even healthy include thalidomide, lead paint, asbestos, and cigarettes.
While some new technologies are dangerous, many others are devoted to sav-
ing lives. Lichtenberg (2005), for example, estimates that new pharmaceuticals ac-
counted for perhaps 40 percent of the rise in life expectancy between 1986 and
2000. MRI machines, better diagnostic equipment, and new surgical techniques
as well as anti-lock brakes, airbags, and pollution scrubbers are all examples of life-
saving technologies. How is growth theory altered when technologies involve life
and death instead of just higher consumption?
Consider what might be called a “Russian roulette” theory of economic growth.
Suppose the overwhelming majority of new ideas are beneﬁcial and lead to growth
in consumption. However, there is a tiny chance that a new idea will be particu-
larly dangerous and cause massive loss of life. Do discovery and economic growth
continue forever in such a framework, or should society eventuallydecide that con-
sumption is high enough andstopplaying the gameof Russianroulette? How is this
conclusion affected if researchers can also develop life-saving technologies?
The answers to these questions turn out to depend crucially on the shape of
preferences. For a large class of conventional speciﬁcations, including log utility,
safetyeventuallytrumps economic growth. The optimal rate of growth maybe sub-
stantially lower than what is feasible, in some cases falling all the way to zero.
This project builds on a diverse collection of papers. Murphy and Topel (2003),4 CHARLES I. JONES
Nordhaus (2003), and Becker, Philipson and Soares (2005) emphasize a range of
economic consequencesofthe highvalue attachedtolife. MurphyandTopel(2006)
extend this work to show that the economic value of future innovations that reduce
mortality is enormous. Weisbrod (1991) early on emphasized that the nature of
health spending surely inﬂuences the direction and rate of technical change. Hall
and Jones (2007) — building on Grossman (1972) and Ehrlich and Chuma (1990) —
is a direct precursor to the present paper, in ways that will be discussed in detail
below. Other related papers take these ideas in different directions. Acemoglu and
Johnson (2007) estimate the causalimpact of changes in life expectancyon income.
Malani and Philipson (2011) provide a careful analysis of the differences between
medical research and research in other sectors.
The paper is organized as follows. Section 2 presents a simple model that il-
lustrates the main results. The advantage of this initial framework is its simplic-
ity, which makes the basic intuition of the results apparent. The disadvantage is
that the tradeoff between growth and safety is a black box. Section 3 then devel-
ops a rich idea-based endogenous growth model that permits a careful study of the
mechanisms highlighted by the simple model. Section 4 discusses a range of em-
pirical evidence that is helpful in judging the relevance of these results, and Section
5 concludes.
2. A Simple Model
At some level, this paper is about speed limits. You can drive your car slowly and
safely, or fast and recklessly. Similarly, a key decision the economy must make is
to set a safety threshold: researchers can introduce many new ideas without regard
to safety, or they can select a very tight safety threshold and introduce fewer ideas
each year, potentially slowing growth.
To develop this basic tradeoff, we begin with a simple two period OLG model.
Suppose an individual’s expected lifetime utility is
U = u(c0) + e−δ(g)u(c), c = c0(1 + g) (1)LIFE AND GROWTH 5
where c denotes consumption, g is the rate of consumption growth, and δ(g) is the
mortality rate so e−δ(g) is the probability an individual is alive in the second period.
A new cohort of young people is born each period, and everyone alive at a point in
time hasthe sameconsumption —this generation’s c0(1+g) is the next generation’s
c0.
To capture the “slow and safely or fast and recklessly” insight, assume δ(g) is an
increasing function of the underlying rate of economic growth. Fastergrowth raises
the mortality rate. In the richer model in the next section, this “black box” linking
growth and mortality will be developed with much more care. Notice, however, that
this approach incorporates the essential idea behind the Russian roulette example
in the introduction.
Each generation when young chooses the growth rate for the economy to max-
imize their expected utility in equation (1). The growth rate balances the concerns
for safetywith the gains from higher consumption. The ﬁrst order condition for this
maximization problem can be expressed as
u′(c)c0 = δ′(g)u(c). (2)
At the optimum, the marginal beneﬁt from higher consumption growth, the left
hand side, equals the marginal cost associated with a shorter life, the right hand
side. This condition can be usefully rewritten as




where ηu,c is the elasticity of u(c) with respect to c.
To make more progress, assume the following functional forms (we’ll generalize
later):
δ(g) = δg (4)




Utility takes the familiar form that features a constant elasticity of marginal utility;6 CHARLES I. JONES
the important role of the constant ¯ u will be discussed momentarily.
2.1. Exponential Growth: 0 < γ < 1
To begin, let’s assume γ < 1 and set ¯ u = 0. In this case, the elasticity of utility with





As long as δ is not too large, the model yields sustained positive growth over time.
For example, if γ = 1/2 and δ = 1/10, then g∗ = 4 and 1 + g∗ = 5: consumption
increases by a factor of 5 across each generation. This comes at the cost of a life
expectancy that is less than the maximum, but such is the tradeoff inherent in this
model.
One cancheck thatthis conclusion is robust to letting ¯ u  = 0. In general, that will
simply introduce transition dynamics into the model with γ < 1. The key elasticity
ηu,c then converges to 1 − γ as consumption gets large, leading to balanced growth
as an asymptotic result.
2.2. The End of Growth: γ > 1
What comes next may seem a bit surprising. We’ve already seen that this simple
model can generate sustained rapid growth for a conventional form of preferences.
What we show now is that in the casewhere γ is larger thanone, the model does not
lead to sustained growth. Instead, concerns about safety lead growth to slow all the
way to zero, at least eventually.
Inthis case,theconstant ¯ uplaysanessentialrole. Inparticular, notice thatwe’ve
implicitly normalized the utility associated with “death” to be zero. For example,
in (1), the individual gets u(c) if she lives and gets zero if she dies. But this means
that u(c) must be greater than zero for life to be worth living. Otherwise, death is
the optimal choice at each point in time. With γ > 1, however, c1−γ
1−γ is less than
zero. For example, this ﬂow is −1/c for γ = 2. An obvious way to make our problemLIFE AND GROWTH 7
Figure 1: Flow Utility u(c) for γ > 1
u(c) = ¯ u + c
1− γ
1−γ





Note: Flow utility is bounded for γ > 1. If ¯ u = 0, then ﬂow utility is negative and
dying is preferred to living.
interesting is to add a positive constant to ﬂow utility. In this case, the ﬂow utility
function is shown in Figure 1. Notice that ﬂow utility is bounded, and the value of ¯ u
provides the upper bound.2













The left-hand side of this expression is increasing in both c0 and in g. As the econ-
omy gets richer over time and c0 rises, then, it must be the case that g declines in
ordertosatisfythisﬁrstordercondition. Theoptimalrateofeconomicgrowthslows
along the transition path.
In fact, one can see from this equation that consumption converges to a steady
state with zero growth. According to the original ﬁrst order condition in (3), the
2As the ﬁgure illustrates, there exists a value of consumption below which ﬂow utility is still neg-
ative. Below this level, individuals would prefer death to life, so they would randomize between zero
consumption and some higher value; see Rosen (1988). This level is very low for plausible parameter
values and can be ignored here. The role of the constant in ﬂow utility is also discussed by Murphy
and Topel (2003), Nordhaus (2003), Becker, Philipson and Soares (2005), and Hall and Jones (2007).8 CHARLES I. JONES
steady state must be characterized by η∗
u,c = δ — that is, the point where the elas-
ticity of the utility function with respect to consumption equals the mortality pa-
rameter. More explicitly, setting g = 0 in (7) reveals that the steady state value of














Because growth falls all the way to zero, mortality declines to zero as well and life
expectancy is maximized.
To see the intuition for this result, recall the ﬁrst order condition for growth:
1 + g = ηu,c/δ. When γ > 1 (or when ﬂow utility is any bounded function), the
marginal utility of consumption declines rapidly as the economy gets richer — that
is, ηu,c declines. This leads the optimal rate of growth to decline and the economy
to converge to a steady state level of consumption.
A crucial implication of the bound on utility is that the marginal utility of con-
sumption declines to zero rapidly. Consumption on any given day runs into sharp
diminishing returns: think about the beneﬁt of eating sushi for breakfast when you
are already having it for lunch, dinner, and your midnight snack. Instead, obtain-
ing extra days of life on which to enjoy your high consumption is a better way to
increase utility.












The left side of this equation is based on the ﬂow value of an additional period of
life, u(c). We divide by the marginal utility of consumption to value this ﬂow in
units of consumption rather than in utils, so u(c)/u′(c) is something like the value
of a period of life in dollars. Then, we consider this value of life as a ratio to actual
consumption.
The right side of this equation shows the value of life as a ratio to consumption
under the assumed functional form for utility. Crucially, for γ > 1, the value of lifeLIFE AND GROWTH 9
rises faster than consumption. As the economy gets richer, concerns about safey
become more important than consumption itself. This is the essential mechanism
that leads the economy to tilt its allocation away from consumption growth and
toward preserving life in the model.
2.3. Generalizing
More generally, it should be clear from equations (9) and (3) that this steady-state
result would obtain with any (well-behaved) bounded utility function: in that case,
the elasticity of utility with respect to consumption falls to zero as consumption
goes to inﬁnity, so the condition ηu,c = δ delivers a steady state.
Interestingly, this same result obtains with log utility. For γ = 1, we have u(c) =
¯ u + logc, and therefore ηu,c = 1/u(c). The elasticity of utility still declines to zero
as consumption gets arbitrarily large, leading to constant consumption in the long
run, even though utility is unbounded.
Alternatively, consider changing the mortality function. If we instead assume
δ(g) = δgθ with θ > 1, then the simple model leads the growth rate to slow to zero,
but only as consumption rises to inﬁnity.3 The implication that consumption will
be constant in the long run, then, seems to be somewhat fragile. The more robust
prediction is that safety considerations may lead consumption growth to slow to
zero.
2.4. Summary of the Simple Model
Thissimple modelisslightymoreﬂexible thanthe“Russianroulette” examplegiven
in the introduction. Rather than choosing between stagnation and a ﬁxed rate of
growth with a small probability of death, the economy can vary the growth rate and
the associated death rate smoothly. This death rate can be given two different in-
terpretations. It may apply independently to each person in the population, so that
3The ﬁrst order condition analogous to equation (3) becomes
g
θ−1(1 + g) =
ηu,c
δθ
which implies that g → 0 only occurs as ηu,c → 0 when γ > 1.10 CHARLES I. JONES
e−δ(g) is the fraction of the population that survives to old age in each cohort. Alter-
natively, it may represent an existential risk that applies to the entire economy.
With γ < 1, the optimal tradeoff between growth and mortality leads to sus-
tained exponential growth, albeit with some positive death rate. In the idiosyn-
chratic interpretation of the death rate, life expectancy is simply less than its maxi-
mum but the economy continues forever. In the existential risk interpretation, the
economy grows exponentially until, with probability one, the existential risk is real-
ized and the economy comes to an end.
A very different result occurs when γ ≥ 1, or more generally when ﬂow utility is
bounded. Inthiscase,themarginalutilityofconsumptioninanyperiodfallsrapidly
as individuals get richer. In contrast, each additional year of life delivers a positive
and growing amount of utility. The result is an income effect that favors safety over
growth. Thegrowthrateoftheeconomyeventuallyfallstozero, lifeexpectancyrises
to its maximum, and consumption may even settle down to a constant. In the exis-
tential interpretation, the economy stops playing Russian roulette and, assuming it
did not get unlucky before reaching the steady state, goes on forever.
3. Life and Growth in a Richer Setting
The simple model in the previous section is elegant and delivers clean results for
theinteraction betweensafetyandgrowth. However,thewayinwhichfastergrowth
raises mortality is mechanical, and it is simply assumed that the economy can pick
whatever growth rate it desires.
In this section, we address these concerns by adding safety considerations to a
standardgrowth modelbasedonthediscoveryofnewideas. Theresultdeepensour
understanding of the interactions between safety and growth. For example, in this
richer model, concerns for safety can slow the rate of exponential growth from 4%
to 1%, for example,but will neverleadto a steady-statelevelof consumption. While
supporting the basic spirit of the simple model, then, the richer model illustrates
some important ways in which the simple model may be misleading.
Themodelbelowcanbeviewedascombiningthe“directionoftechnicalchange”LIFE AND GROWTH 11
work by Acemoglu (2002) with the health-spending model of Hall and Jones (2007).
That is, we posit a standard idea-based growth model where there are two types of
ideasinsteadofone: ideasthatenhanceconsumption andideasthatsavelives. The
key allocative decisions in the economy are (i) how many scientists to put into the
consumption versuslife-savingsectors,and(ii)how manyworkers toputinto using
these ideas to manufacture goods.
A looser interpretation of the model goes like this. New technologies have con-
sumptionpropertiesandlife-relatedproperties. Researchersmustdecidehowmuch
effort to put into each dimension. For instance, a new automobile engine can be
made to be more powerful or to pollute less. Or researchers can spend their time
making a new insulating material either safer or easier to manufacture.
3.1. The Economic Environment
The economy features two main sectors, a consumption sector and a life-saving
sector. On the production side, both sectors are quite similar, and each looks very
much like the Jones (1995) version of the Romer (1990) growth model. In fact, we’ll
purposefully make the production side of the two sectors as similar as possible (i.e.
using the same parameters) so it will be clear where the results come from.

















Each sector uses a variety of intermediate goods to produce output with the same
basic production function. The main difference is that different varieties — differ-
ent ideas — are used for each sector: At represents the range of technologies avail-
able to produce consumption goods, while Bt represents the range usedto produce
life-saving goods. It might be helpful to think of the zit as purchases of different
types of pharmaceuticals and surgical techniques. But we have in mind a broader
category of goods as well, such as pollution scrubbers in coal plants, seatbelts and
airbags, child safety locks, lifeguards at swimming pools, and safety regulations at
construction sites.12 CHARLES I. JONES
Once the blueprint for a variety has been discovered, one unit of labor can be
used to produce one unit of that variety. The number of people working as labor is













People can produce either goods, as above, or ideas. When they produce ideas,
we call them scientists, and the production functions for new ideas are given by
˙ At = ¯ aSλ
atA
φ




where we assume φ < 1. Once again, notice that we assume the same parame-
ters for the idea production functions in the two sectors; this assumption could be
relaxed but is useful because it helps to clarify where the main results come from.
The resource constraints on scientists and people more generally are
Sat + Sbt ≤ St (13)
and
St + Lt ≤ Nt. (14)
That is, Nt denotes the total number of people, who can work as scientists or labor.
In turn, scientists and labor can work in either the consumption sector of the life-
saving sector.




t , ht ≡ Ht/Nt. (15)
Purchases of new drugs, better surgical techniques, pollution scrubbers, and seat-
belts can save lives.
Total mortality is ˆ δ + δt, which includes a parameter ˆ δ that captures the funda-
mentalunderlyingrateofmortalitynotsusceptibletotechnologicalprogress(whichLIFE AND GROWTH 13
mayormaynotbezero). We assumeanexogenous fertilityrateof ˆ nandlet ¯ n ≡ ˆ n−ˆ δ
denote the exogenous piece of population growth, apart from δt. Therefore the law
of motion for population is
˙ Nt = (¯ n − δt)Nt. (16)




e−ρtu(ct)Λtdt, ˙ Λt = −(ˆ δ + δt)Λt (17)
where





, ct ≡ Ct/Nt. (18)
Λt istheprobability thatanindividualaliveatdatezerosurvivesuntildatet;mortal-
ity reduces this survival probability. Flow utility takes a standard CRRA form, aug-




Sbt,St,Lt,Nt,δt — and 11 equations — equations (10) through (15), including the
deﬁnitions for ht and ct (we are not counting lifetime utility and ﬂow utility in this
numeration).
There are, not surprisingly then, three key allocative decisions that have to be
made in the economy, summarized by three allocative fractions st,ℓt, and σt:
1. How many scientists make consumption ideas versus life-saving ideas: st ≡
Sat/St.
2. How many workers make consumption goods versus life-saving goods: ℓt ≡
Lct/Lt. (Given the symmetry of the setup, it is efﬁcient to allocate the xit and
the zit symmetrically across varieties, so we will just impose this throughout
the paper to simplify things.)
4As usual, ρ must be sufﬁciently large given growth so that utility is ﬁnite. We provide a precise
version of this condition below.14 CHARLES I. JONES
3. How many people are scientists versus workers: σt ≡ St/Nt.
3.3. A Rule of Thumb Allocation
For reasons that will become clear, it is convenient to begin with a simple “rule of
thumb” allocation, analogous to Solow’s assumption of a ﬁxed saving rate in his
version of the neoclassical growth model.
In particular, we consider the following rule of thumb allocation: st = ¯ s, ℓt = ¯ ℓ,
andσt = ¯ σ,whereeachofthesenewparametersisbetween0and1. Thatis,wecon-
siderputting aﬁxedfraction ofourscientists ineachresearchsector,aﬁxedfraction
of our workers in each goods sector, and let a ﬁxed fraction of the population work
as scientists.
It is straightforward to show the following result:
Proposition1 (BGPunder the Rule of Thumb Allocation): Under the rule of thumb
allocation where st = ¯ s, ℓt = ¯ ℓ, and σt = ¯ σ, all between 0 and 1, there exists an
asymptotic balanced growth path such that as t → ∞, growth is given by5















This is basically the expected outcome in a growth model of this ﬂavor. With
labor allocated symmetrically within the consumption and life sectors, the produc-
tion functions are Ct = Aα
t Lct and Ht = Bα
t Lht. The idea production functions are
also symmetric in form. For instance,
˙ At
At = ¯ aSλ
at/A
1−φ




t must grow at the same rate. Since the growth rate of scientists is
pinned down by the population growth rate, this means the growth rate of At (and
Bt) will be as well. Therefore Bt goes to inﬁnity, which means that the mortality rate
δt falls to zero. And so on...
5These results, and indeed the results throughout the remainder of this paper, are of the following
form: limt→∞ gct = g
∗
c, and so on.LIFE AND GROWTH 15
The rule of thumb allocation suggests that this model will deliver a balanced
growth path with life expectancy rising to its maximum. Moreover, growth is bal-
anced in a particular way: technical change occurs at the same rate in both the
consumption and life sectors, so the relative price of the consumption and life ag-
gregates is constant. And by assumption, a constant fraction of labor and scientists
work in each sector. Of course, we could have altered some of these results simply
by making the elasticity of substitution or the parameters of the idea production
function differ between the two sectors. But that’s not where we wish to go. For the
moment, simply note that everything is nicely behaved and straightforward in the
rule of thumb allocation.
3.4. The Optimal Allocation
Somewhat surprisingly, our rule of thumb allocation turns out not to be a partic-
ularly good guide to the dynamics of the economy under the optimal allocation.
Instead, as suggested by the simple “Russian roulette” model at the start of this pa-
per, there is a sense in which consumption growth is slower than what is feasible
because of a shift in the allocation of resources when diminishing returns to con-
sumption are sufﬁciently strong.
There are many interesting questions related to welfare theorems in this type
of model: is a decentralized market allocation efﬁcient? One can imagine various
externalities related to safety, particularly when “existential” risks are under con-
sideration. For now, however, we will put these interesting questions aside. Our
concern instead is with how safety considerations affect the economy even when
resources are allocated optimally.
The optimal allocation of resources is a time path for ct,ht,st,ℓt,σt,At,Bt,Nt,δt






Ntu(ct)e−ρtdt s.t. (22)16 CHARLES I. JONES
ct = Aα
t ℓt(1 − σt) (23)
ht = Bα
t (1 − ℓt)(1 − σt) (24)















function (e.g. bysetting N0 = 1), or it canbe viewed as a social welfare function that
gives equal weight to each live person’s ﬂow utility, regardless of age.
To solve for the optimal allocation, we deﬁne the Hamiltonian:









t + vt(¯ n − δt)Nt, (28)
where ct = Aα
t ℓt(1−σt) and δt = h
−β
t = (Bα
t (1−ℓt)(1−σt))−β. The costate variables
— pat,pbt, and vt — capture the shadow values of an extra consumption idea, an
extra life-saving idea, and an extra person to maximized welfare.
Using the Maximum Principle and solving the ﬁrst-order necessary conditions
for the optimal allocation, we can derive several results. The most important of
these is given in the next proposition (proofs for this an the remaining propositions
are given in the appendix).
Proposition2 (Optimal Growth with γ > 1 + β): Assume that the marginal utility
of consumption falls rapidly, in the sense that γ > 1 + β. Then the optimal alloca-
tion features an asymptotic balanced growth path such that as t → ∞, the fraction
of labor working in the consumption sector ℓt and the fraction of scientists making
consumption ideas st both fall to zero at constant exponential rates, and asymptotic




−¯ g (γ − 1 − β)
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g∗
δ = −β¯ g, g∗




ℓ = ¯ g  
1 + β(1 + αλ
1−φ)
1 + (γ − 1)(1 + αλ
1−φ)
< ¯ g. (32)
Thisproposition echoesthekeyresultfromthesimple“RussianRoulette”model
atthe start of the paper: if the marginal utility of consumption runs into sufﬁciently
sharp diminishing returns, safety considerations alter the essential nature of op-
timal growth. While in the toy model, it was possible for consumption growth to
cease, the more micro-founded model given here displays a more subtle result.
First, the economy optimally settles down to an asymptotic balanced growth
path, but along this path, consumption grows at a rate that is slower than what is
feasible. This can be seen by comparing the consumption growth rates for the rule
of thumb allocation in (21) and the optimal allocation in (32): when γ − 1 > β,
g∗
c < ¯ g.
Second, the proximate cause of this slower growth is an exponential shift in the
allocation of resources. In particular, both the fraction of scientists and the fraction
of workers engaged in the consumption sector — st and ℓt — fall exponentially over
time along the BGP. To see how this slows growth, recall the production functions
for ideas










The share 1 − st in the life-saving sector converges to one, leading to the expected
result that g∗
B = λ¯ n/(1 − φ). However, the share st in the consumption ideas pro-
duction function falls exponentially toward zero. The exponential shift of scientists
out of this sector slows gA relative to gB, ultimately slowing consumption growth as
well.
A very nice feature of this result is that it makes a clear prediction: we should
see the composition of research shifting over time away from consumption ideas
and toward life-saving ideas if the model is correct and if the marginal utility of
consumption falls sufﬁciently fast. We will provide empirical evidence on this pre-
diction later on in the paper.
To understand the underlying reason for this structural change in the economy,18 CHARLES I. JONES
consider the following equation, which is the ﬁrst-order condition for allocating la-







The left-side of this equation is just the ratio of labor working in the life sector to la-
bor working in the consumption sector. This equation says that the ratio of workers
is proportional to the ratio of what these workers can produce. In the numerator is
the death rate δt multiplied by the value of a life in utils, vt: this is the total value of
what can potentially be gained by making a life-saving good. The denominator, in
contrast, is proportional to what can be gained by making consumption goods: the
level of consumption multiplied by the marginal utility of consumption to put it in
utils, like the numerator.
In the analysis of this equation, it turns out to be useful to deﬁne ˜ vt ≡ vt
u′(ct)ct
— the value of a life in consumption units as a ratio to the level of consumption.
The allocation of workers then depends on the product δt˜ vt. In fact, as shown in
the appendix, the allocation of scientists depends on exactly this same term — see
equation (42).
Over time, the fraction of deaths that can potentially be avoided, δt, declines.
However, the value of each life rises. When γ > 1, the value of life rises even as a
ratio to consumption, so ˜ vt rises. Then, it is a race: δt falls at a rate proportional to
β, while ˜ vt rises at a rate proportional to γ − 1. Hence the critical role of γ − 1 − β.
In particular, when γ is large, as in the proposition we’ve just stated, the value of
life rises very rapidly, so that δt˜ vt rises to inﬁnity. In this case, the optimal allocation
shifts all the labor and scientists into the life sector: the value of the lives that can
be saved rises so fast that it is optimal to devote ever-increasing resources to saving
lives.
3.5. The Optimal Allocation with γ < 1 + β
What happens if the marginal utility of consumption does not fall quite so rapidly?
The intuition is already suggested by the analysis just provided, and the result isLIFE AND GROWTH 19
given explicitly in the next proposition.
Proposition3 (Optimal Growthwithγ < 1+β): Assumethatthemarginalutilityof
consumption falls, but not too rapidly, in the sense that γ < 1 + β. Then the optimal
allocation features an asymptotic balanced growth path such that as t → ∞, the
fraction of labor working in the life sector ˜ ℓt ≡ 1 − ℓt and the fraction of scientists
making life-saving ideas ˜ st ≡ 1 − st both fall to zero at constant exponential rates,
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and the exact values for g∗
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While if γ ≤ 1:
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This proposition shows that when γ < 1 + β, the results ﬂip-ﬂop. That is, there
is still a trend in the allocation of scientists and workers, but the trend is now away
from the health/life sector and towards the consumption sector. In this case, the
death rate falls faster than the value of life rises. Looking back at equation (33), the
denominator u′(ct)ct risesfasterthanthenumerator: thegreatergainisinproviding
consumption goods rather than in saving lives. We once again get an unbalanced
growth result, but now it is the consumption sector that grows faster.20 CHARLES I. JONES
3.6. “Interior” Growth when 1 < γ = 1 + β
Proposition4 (Optimal Growth with 1 < γ = 1 + β): Assume that the marginal
utility of consumption falls rapidly (γ > 1) and assume the following knife-edge con-
dition relating preferences and technology: γ = 1 + β. Then the optimal allocation
features an asymptotic balanced growth path such that as t → ∞, the key allocation
variables ℓt and st settle down to constants strictly between 0 and 1, and asymptotic











= ¯ g, g∗
δ = −β¯ g.
This is the one case where growth is “balanced” in the sense that the consump-
tion and life sectors grow at the same rate and labor and scientists do not all end up
in one sector. But, as stated above, this requires a somewhat arbitrary knife-edge
condition relating technology and preferences.6
3.7. Discussion
The simple toy model at the start of the paper and the richer model developed sub-
sequently lead to slightly different conclusions. In the simple model, consumption
growth falls to zero when the marginal utility of consumption diminishes rapidly,
while in the richer model the growth rate is only slowed by some proportion. Why
the difference?
The answer turns on functional forms and modeling choices about which we
have relatively little information. In the simple model, the mortality rate depends
on the growth rate of the economy rather than on the level of technology in the life-
saving sector, and this difference is evidently quite important. One can imagine a
more sophisticated version of the simple model that would preserve its stronger re-
sults. Forexample —along the lines ofthe Russianroulette example from the intro-
duction — suppose that most ideas are safe, but some ideas are dangerous and kill
6It turns out that even γ = 1 + β is not enough to get balanced growth when γ < 1. In this case, all
the workers and scientists still end up moving to the consumption sector, as in Proposition 3.LIFE AND GROWTH 21
off a fraction of the population. If each idea raises consumption by a constant pro-
portion (as in many Schumpeterian quality-ladder models like Aghion and Howitt
(1992)), it seems likely that growth would optimally cease if the marginal utility of
consumption falls rapidly.
Thegeneralresultofthispaper,then,isthatconcerns forsafetycanslowgrowth,
with the precise nature of the slowdown depending on modeling details.
4. Empirical Evidence
A useful feature of the main model in this paper is that it makes stark predictions
regarding the composition of research. Depending on the relative magnitudes of
γ − 1 and β, the direction of technical change should shift either toward or away
from life-saving technologies. In particular, if γ is large — so that the marginal util-
ity of consumption declines rapidly — one would expect to see the composition
of research shifting toward life-saving technologies, thereby slowing consumption
growth.
In this section, we discuss a range of evidence on β, γ, and the composition of
research. While not entirely decisive, the bulk of the evidence is very much consis-
tentwiththeﬁrstcaseweconsidered, wherethere isanincomeeffectforlive-saving
technologies and consumption growth is slowed.
4.1. The Composition of Research
One might think the main prediction on the composition of research would be an
easy prediction to test: surely there must be readily-available statistics on research
spending by the health sector of the economy. Unfortunately, this is not the case.
The main reason appears to be because both the spending and performance of
health research is done in several different organizations in the economy: indus-
try, government, non-proﬁts, and academia. Thus, the construction of such num-
bers requires merging the results of different surveys, being careful to avoid double
counting, considering changes in the surveys over time, and so on. Between the22 CHARLES I. JONES
Figure 2: The Changing Composition of U.S. R&D Spending
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Note: The graph shows the riseinthe share of R&D spending inthe United States
that is devoted to health, according to several different measures. See the Data
Appendix for sources and methodology.
1970s and the early1990s, the NIHundertook this calculation andreported ahealth
research number. But, unfortunately, I have not been able to ﬁnd any other source
that does this for the last twenty years.
As an imperfect substitute, I have put together some of the numbers myself. I’m
far from an expert on these surveys, so the numbers I discuss below are surely im-
perfectanddonotadequatelyaddresstheconcerns outlined above. Forthisreason,
I do not report a single time series, but rather show results from a number of differ-
entcalculations. Fortunately, these allstrongly point in the samedirection, sowhile
we do not end up with a precise time series for health R&D, I think we do end up
with consistent evidence that speaks to the topic of this paper.
The details of my calculations are discussed in the Data Appendix, and the re-
sults are provided in two ﬁgures. Figure 2 documents the changing composition of
R&D spending in the United States. Four different time series are shown, includ-
ing the original NIH estimates and a long time series on non-commercial healthLIFE AND GROWTH 23
Figure 3: The Changing Composition of OECD R&D Spending














                                      Health Share of R&D (percent)
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Note: The trend toward health is apparent in OECD measures of R&D expendi-
tures as well. The OECD estimate reported here includes data from the United
States, Canada, France, Germany, Italy, Japan, Spain, and the United Kingdom.
See the Data Appendix for sources and methodology.
research from the National Health Expenditure Accounts of the Centers for Medi-
care and Medicaid Services (CMMS). The remaining two time series add estimates
of commercial research to the CMMS estimate, using two different collections of
surveys by the National Science Foundation. The fact that the NIH series and the
CMMS+NSF series coincide during overlapping years is somewhat reassuring.
The message from Figure 2 is quite clear. Whether we look at non-commericial
research or the broader estimates for total research, the composition of R&D ap-
pears to be shifting distinctly toward health over time. For example, the earliest es-
timates from 1960 suggestthatthe healthsector accounted for only about 7 percent
of all R&D, while the most recent estimates from 2007 are around 25 percent.
Ofcourse,life-savingtechnologies areinventedaroundthe world, not justinthe
United States. Figure 3 uses OECD sources to study how the composition of R&D
is changing internationally. This data is only available since 1991 but tells the same24 CHARLES I. JONES
basicstory: the composition ofresearchisshifting distinctly toward health. In1991,
around 9 percent of OECD research spending was on health, and this share rose to
16 percent by 2006. The ﬁgure also shows the corresponding share for the United
States (estimated using slightly different assumptions with these OECD sources),
conﬁrming the sharp rise that we saw earlier in Figure 2.
This evidence on the composition of research is helpful in that it addresses one
of the clear predictions of the model. Of course, this is not an entirely compelling
test of the model, as there are other possible explanations for the changing com-
position of research. For example, perhaps the rise in the share of health spending
in the economy is due to other factors, and health research is simply responding to
these factors as well. Also, health research is an imperfect proxy for efforts devoted
to life-saving technologies; research on pollution scrubbers and highway safety will
not be included, for example.
4.2. Empirical Evidenceon β
The parameter β is readily interpreted as the elasticity of the mortality rate with re-
spect to real health expenditures. A plausible upper bound for this parameter can
then be obtained by considering the relative trends in mortality and health spend-
ing: this calculation would attribute all the decline in mortality to health spending,
which is surely an overestimate given the likely importance of other factors.
According to Health, United States 2009, age-adjusted mortality rates fell at an
averageannualrateof1.2%between1960and2007,whileCPI-deﬂatedhealthspend-
ing rose at an average annual rate of 4.1%.7 The ratio of these two growth rates
gives an estimate of the upper bound for β of 0.291. Hall and Jones (2007) con-
duct a more formal analysis along these lines using age-speciﬁc mortality rates,
age-speciﬁc health spending, and allowing for other factors to enter. For people
between the ages of 20 and 80, they ﬁnd estimates for this elasticity ranging from
0.10 to 0.25.
7See Tables 26 and 122 of that publication, available at http://www.cdc.gov/nchs/hus.htm.LIFE AND GROWTH 25
4.3. Estimates of γ
Given the upper bound for β just reported, life considerations will dominate in the
model if γ is larger than about 1.3. In the most common way of specifying pref-
erences for macro applications, the coefﬁcient of relative risk aversion, γ in our
notation, equals the inverse of the elasticity of intertemporal substitution. Large
literatures on assetpricing (Lucas1994) andlabor supply(Chetty 2006) suggestthat
γ > 1isareasonablevalue,andvaluesabove1.5arequitecommoninthisliterature.
Evidence on the elasticity of intertemporal substitution, 1/γ in our notation, is
more mixed. The traditional view, supported by Hall (1988), is that this elasticity
is well below one, consistent with the case of γ > 1.3. This view is supported by
a range of careful microeconometric work, including Attanasio and Weber (1995),
Barsky,Juster,KimballandShapiro (1997),andGuvenen(2006);seeHall(2009) fora
survey of this evidence. On the other hand, Vissing-Jorgensen and Attanasio (2003)
and Gruber (2006) ﬁnd evidence that the elasticity of intertemporal substitution is
greater than one, suggesting that γ < 1 could be appropriate.
4.4. Empirical Evidenceon the Value of Life
Direct evidence on how the value of life changes with income — another way to
gauge the magnitude of γ — is surprisingly difﬁcult to come by. Most of the em-
pirical work in this literature is cross-sectional in nature and focuses on getting a
single measure of the value of life (or perhaps a value by age); see Ashenfelter and
Greenstone (2004), for example. There are a few studies that contain important
information on the income elasticity, however. Viscusi and Aldy (2003) conduct a
meta-analysis and ﬁnd that across studies, the value of life exhibits an income elas-
ticity below one. On the other hand, Costa and Kahn (2004) and Hammitt, Liu and
Liu (2000) consider explicitly how the value of life changes over time. These stud-
ies ﬁnd that the value of life rises roughly twice as fast as income, consistent with
γ > 1.3.26 CHARLES I. JONES
4.5. Evidence from Health Spending
The key mechanism at work in this paper is that the marginal utility of consump-
tion falls quickly if γ > 1, leading the value of life to rise faster than consumption.
This tilts the allocation in the economy awayfrom consumption growth andtoward
preserving lives. Exactly this same mechanism is at work in Hall and Jones (2007),
which studies health spending. In that paper, γ > 1 leads to an income effect: as
the economy gets richer over time (exogenously), it is optimal to spend an increas-
ing fraction of income on health care in an effort to reduce mortality. The same
force is at work here in a very different context. Economic growth combines with
sharply diminishing marginal utility to make the preservation of life a luxury good.
The novel ﬁnding is that this force has ﬁrst-order effects on the determination of
economic growth itself.
What evidence is there for an income elasticity of health spending larger than
one? Figure 4 shows some international evidence. Health spending as a share of
GDP is rising in many countries of the world, not only in the United States. Indeed,
for the 19 OECD countries reporting data in both 1970 and 2006 (many not shown),
all experienced a rising health share.
Acemoglu, Finkelstein and Notowidigdo (2009a) estimate an elasticity of hospi-
tal spending with respect to transitory income of 0.7, less than one, using oil price
movements to instrument local income changes at the county level in the south-
ern part of the United States. While useful, it is not entirely clear that this bears on
the keyparameterhere, asthatpaper considers income changes thatare temporary
(and hence might reasonably be smoothed and not have a large effect on health
spending) and local (and hence might not alter the limited selection of health in-
surance contracts that are available).
4.6. Growth in Health and Non-Health Consumption
The results from our model suggest that, apart from a knife-edge case, the compo-
sition of research will shift toward either the consumption sector or the life-saving
sector. Moreover, at least insofar as the parameters of the idea production functionLIFE AND GROWTH 27
Figure 4: International Evidence on the Income Effect in Health Spending
















Note: Data are from OECD Health Data 2009 and are reported every 10 years, except for
the last observation from 2006.
are similar in those two sectors (and we have no real evidence pushing us one way
or the other on this), the sector that sheds its researchers will grow more slowly in
the long run.
Thisprediction promptsustolookatthehistoricalevidenceonthegrowthofper
capita consumption for both the health and non-health sectors, respectively. Fig-
ure 5 shows this evidence, taken from the National Income and Product Accounts
for the United States.
The ﬁgure shows twolines foreachsector, differing according to whichprice de-
ﬂators are used. The “ofﬁcial” lines report the results usingthe ofﬁcial BEA deﬂators
forhealthandnon-healthconsumption. Theseresultsalreadysuggestfastergrowth
in health than in consumption, consistent with the evidence on the composition of
research.
There is ample evidence, however, that serious measurement problems asso-
ciated with quality change plague the construction of these deﬂators. Triplett and28 CHARLES I. JONES
Figure 5: Health and Consumption
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Note: The plot showsrealper capitaconsumptionexpenditures forhealth andnon-health
in the United States. Two different methods are used to deﬂate nominal expenditures.
The “ofﬁcial” lines are deﬂated by the price indices constructed by the BEA, which show
more rapid price increases in the health sector. The “pce” lines are both deﬂated by the
overall deﬂator for personal consumption expenditures, implicitly assuming that techni-
calchange inthetwosectors occurs atthesamerate(aconservativeassumptiongiventhe
general empirical evidence reported in this paper).
Bosworth(2000),forexample,showthattheyimplynegativelaborproductivity growth
in the health sector, a ﬁnding that rings hollow given the rapid technological ad-
vances in that sector. Many case studies of particular health treatments ﬁnd that
quality-adjusted prices are actually falling rather than rising relative to the CPI.8
The “pce” measures in Figure 5 therefore deﬂate both nominal health spending and
8Cutler, McClellan, Newhouse and Remler (1998)ﬁnd that the real quality-adjusted price for treat-
ing heart attacks declines at a rate of 1.1 percent per year between 1983 and 1994. Shapiro, Shapiro
and Wilcox (1999) examine the treatment price for cataracts between 1969 and 1994. While a CPI-like
price index for cataracts increased at an annual rate of 9.2 percent over this period, their alternative
price index, only partially incorporating quality improvements, grew only 4.1 percent per year, falling
relativeto the total CPI at a rate of about 1.5 percent per year. Berndt, Bir, Busch, Frank and Normand
(2000)estimatethat the price of treating incidents of acute phase majordepressiondeclined innomi-
nal terms by between 1.7percent and 2.1percent per year between 1991and 1996,corresponding to a
real rate of decline of more than 3 percent (though over a relatively short time period). Lawver (2011)
obtain similar results using a structural model and more aggregate data.LIFE AND GROWTH 29
nominalconsumption spendingbytheoverallNIPAdeﬂatorforpersonalconsump-
tion expenditures, implicitly assuming rates of technological change are the same
in the two sectors. Of course, given the changing composition of research, eventhis
correction arguably falls short. Nevertheless,one cansee that it suggests a large dif-
ference in growth between the two sectors, with growth in health averaging 4.67%
per year between 1950 and 2009, versus only 1.84% for per capita consumption.
Iftheeconomywere alreadyinsteadystate,the growth ratesreported inFigure5
would be direct evidence on the magnitude ofthe “growth drag” associatedwith life
considerations, andthis dragissubstantial: 1.84/4.67 ≈ 0.4, forexample,suggesting
that consumption growth is reduced to only 40% of its feasible rate because of the
rising importance of life.
Unfortunately, the evidence on the composition of research suggests the econ-
omy is far from its steady state, since the research share is well below one. This
evidence on the growth drag, then, is only suggestive. However, as the next section
shows, one can calibrate the model to get an estimate of the growth drag that is in
the same ballpark as this historical evidence.
4.7. Calibrating the Growth Drag
We have discussed a range of evidence in this section — the shift in the composi-
tion of research toward health, empirical estimates of β and γ, how the value of life
changes with income, the rise in health spending as a share of GDP, and the histor-
ical evidence on the growth rates of health spending versus non-health consump-
tion. While none is entirely decisive, the evidence suggests that the possibility of an
income effect favoring life-saving technologies should be considered carefully. The
case studied in Proposition 2 where γ − 1 > β may be the relevant one.
Here, we follow this logic and, using a range of parameter values consistent with
the evidence just discussed, report the magnitude of the “growth drag” that is im-
plied. More precisely, recall that according to Proposition 2, long-run growth rates30 CHARLES I. JONES





= ¯ g (38)
g∗
c = ¯ g  
1 + β(1 + αλ
1−φ)
1 + (γ − 1)(1 + αλ
1−φ)
< ¯ g. (39)
That is, when γ − 1 > β, the consumption sector grows more slowly than the health
sector — and more slowly than what is feasible — by a factor that is given in the last
equation.
To estimate this factor, we require estimates of γ, β, and αλ
1−φ. We’ve already dis-
cussed evidence on the ﬁrst two of these above. Notice from equation (38) that the
last is just given by the factor by which the long-run growth rate of the health sector
is “marked up” over the rate of population growth. Estimates of this factor for the
economy as a whole are discussed in Jones and Romer (2010); a broad but plausi-
ble range for this factor is [1/2,2]; larger values would simply make the growth drag
even more dramatic.
Table 1 reports estimates of the “growth drag” factor in equation (39). These
factors range from a low of 0.33 to a high of 0.79, with the mean value equal to 0.56.
That is, according to the mean value, long-run growth in the consumption sector is
only 56% of its feasible rate in the optimal allocation. It would be feasible to keep
the research shares constant and let consumption grow much faster, but the rising
value of life means this is not optimal.
This growth drag calculation illustrates a deeper conceptual point about the
model. The standard interpretation of semi-endogenous growth models (like this
one) is that conventional policies cannot affect the long-run growth rate. However,
that is incorrect in this case. Policies that alter the rate at which the consumption
sector sheds researchers can change the magnitude of the growth drag and hence
affect the long-run growth rate of consumption.LIFE AND GROWTH 31
Table 1: The Growth Drag
β = .25 β = .10
αλ
1−φ γ = 1.5 γ = 2 γ = 1.5 γ = 2
0.50 0.79 0.55 0.66 0.46
1.00 0.75 0.50 0.60 0.40
2.00 0.70 0.44 0.52 0.33
Note: The table reports the ratio of gc to gh in steady state according to Proposition 2
for various values of the parameters. That is, it reports the factor by which consump-




1−φ ). The mean across the various estimates is 0.56.
4.8. A FutureGrowth Slowdown?
Close to the balanced growth path, the share of research devoted to health would
be close to one, so that the percentage increases in the health research share would
be small and not contribute signiﬁcantly to growth. In contrast, the percentage
declines in the consumption research share would be large, signiﬁcantly slowing
growth in that sector. In recent decades, however, the economy appears to be far
enough from steady state that the opposite is still occuring: a growing health re-
search share boosts growth in that sector. Similarly, the percentage decline in the
consumptionshareofresearchisrelativelymodest,whichmeansthatconsumption
is growing faster than its long run rate.
To get a rough sense of the magnitudes involve, recall that the health share of
researchin Figure 2 is estimatedto have risen from about 7% to about 25% between
1960 and 2007. This corresponds to an average annual growth rate of about 2.7%,
which is large relative to the overall growth rate of R&D. In constrast, the consump-
tion researchsharehasfallenfrom 93%to75%overthe sameperiod, corresponding
to an average annual growth rate of -0.46%. This is more in line with calibrated val-
ues of the long-run decline in the consumption research share.32 CHARLES I. JONES
The implication of this argument is that some of the hypothetical growth drag
that we have calculated applies to future growth, particularly in terms of the pro-
duction of life-saving goods. That is, this channel provides a mechanism through
which health spending growth — which makes up an increasing portion of GDP
growth — would be predicted to slow in the future. The magnitudes computed for
the growth drags suggest that this slowdown could be substantial.
4.9. Sustainable Growth and the Environment
This paper is also related to the literature on sustainable growth and the environ-
ment; for example, see Solow (1974), Stiglitz (1974), Gradus and Smulders (1993),
and Aghion and Howitt (1998, Ch. 5). Particularly relevant are Stokey (1998) and
Brock and Taylor (2005), who study the environmental Kuznets curve in which pol-
lution ﬁrst rises and then falls with economic development. In these papers, pol-
lution enters the utility function as a cost in an additively separable fashion from
consumption. These models feature an income effect for γ > 1 because the utility
from growing consumption is bounded. This leads to a “growth drag” from the en-
vironment: growth is slower than it would otherwise be because of environmental
concerns. While the key issues here are very distinct — the utility costs of pollu-
tion in one case versusthe loss of life associatedwith dangerous technologies in the
other — it is interesting that the curvature of marginal utility plays a central role in
both and can slow growth.
One of the ways in which pollution has been mitigated in the United States is
through the development of new, cleaner technologies. Examples include scrub-
bers that remove harmful particulates from industrial exhaust and catalytic con-
verters that reduce automobile emissions. Researchers can spend their time mak-
ing existing technologies safer or inventing new technologies. Rising concerns for
safetyleadthemtodiverteffortawayfromnewtechnologies, whichmayslowgrowth.
Acemoglu,Aghion, BursztynandHemous(2009b)explorethiskindofdirectedtech-
nical change in a model of growth and the environment.LIFE AND GROWTH 33
5. Conclusion
Technological progress involves life and death, and augmenting standard growth
models to take this into account leads potentially to ﬁrst-order changes in the the-
ory of economic growth. This paper explores these possibilities, ﬁrst in a simple
“Russianroulette” style model andthen in aricher modelin which growth explicitly
dependsonthediscoveryofnewideas. Theresults dependsomewhatonthedetails
of the model and, crucially, on how rapidly the marginal utility of consumption de-
clines. Itmaybeoptimalforconsumption growth tocontinue exponentially despite
the presence of life-and-death considerations. Or it may be optimal for growth to
slow to zero, even potentially leading to a steady-state level of consumption.
The intuition for the slowing of growth turns out to be straightforward. For
a large class of standard preferences, safety is a luxury good. The marginal util-
ity associated with more consumption on a given day runs into sharp diminish-
ing returns, and ensuring additional days of life on which to consume is a natural,
welfare-enhancing response. When the value of life rises faster than consumption,
economic growth leads to a disproportionate concern for safety. This concern can
be so strong that it is desirable that growth slow down.
This paper suggests a number of different directions for future research on the
economics of safety. It would clearly be desirable to have precise estimates of the
value of life and how this has changed over time; in particular, does it indeed rise
faster than income and consumption? More empirical work on how safety stan-
dardshavechangedovertime—andestimatesoftheirimpactsoneconomicgrowth
— would also be valuable. Finally, the basic mechanism at work in this paper over
time also applies across countries. Countries at different levels of income may have
very different values of life and therefore different safety standards. This may have
interesting implications for international trade, standards for pollution and global
warming, and international relations more generally.34 CHARLES I. JONES
A Appendix: Derivations and Proofs
This appendix contains outlines of the proofs of the propositions reported in the
paper.
Asaprelude tothesepropositions, weﬁrstconsider theoptimalallocation prob-
lem in equations (22) through (27). Using the Hamiltonian in (28) and applying the

































































plus the three standard transversality conditions.





This variable denotes the ratio of the value of life to consumption per person.
Proof of Proposition 2. Optimal Growth with γ > 1 + β
The essence of the result is that the key allocation variables st and ℓt decline
exponentially to zero at a constant rate. This exponential shift of scientists toward
the life sector slows the growth rate of consumption ideas. To derive the result, weLIFE AND GROWTH 35
use the various ﬁrst order conditions for the optimal allocation.
1. Look back at the ﬁrst-order condition characterizing the allocation of scien-
tists, equation (FOC: s). To solve for this allocation, we need to solve for the
relative price of ideas, pb/pa. From equations (FOC: A) and (FOC: B), we have
pat =
αNtu′(ct)ct/At
ρ − gpat − φgAt
and pbt =
αβNtvtδt/Bt
ρ − gpbt − φgBt
. (40)
Acondition ontheparametervalues(basicallythatρissufﬁcientlylarge)keeps
the denominators of these expressions positive.
This means that the relative price satisﬁes
pbtBt
patAt
= βδt˜ vt  
ρ − gpat − φgAt
ρ − gpbt − φgBt
. (41)
2. Substituting this expression into (FOC: s) yields
1 − st
st
= βδt˜ vt  
ρ − gpat − φgAt





Recallfrom (FOC: ℓ) that 1−ℓt
ℓt = βδt ˜ vt, soboth of these keyallocation variables
depend on δt˜ vt, that is, on the race between the decline in the mortality rate
and the possible rise in the value of life relative to consumption. The next
several steps characterize the behavior of δt˜ vt, which we will then plug back
into this expression.










This is a key expression: the value of having an extra person in the economy
(as a ratio to consumption) depends crucially on the extra utility that person
enjoys — that’s the ﬁrst term in the numerator and the one that matters most
inwhatfollows. Thesecondterminthenumeratorreﬂectstheadditional con-
sumption ideas that an extra person will generate. The denominator essen-36 CHARLES I. JONES
tially converts this ﬂow dividend (the numerator) into a present discounted
value. Notice that the discount rate is reduced by the additional health ideas
that the person will generate, which lets the person live longer to enjoy more
utility and produce even more ideas in the future.









Since γ > 1, along an asymptotic balanced growth path where ct → ∞,
g˜ v = (γ − 1)gc. (44)
5. Now let’s guess that the solution for the asymptotic balanced growth path
takes the following form: st and ℓt fall toward zero at a constant exponential
rate, while σt → σ∗ and nt → ¯ n. We’ll see that the key condition delivering this
result will be γ > 1 + β.
6. Under this proposed solution, consumption growth is
gc = αgA + gℓ = αgA + gs (45)
wherethe lastequalitycomesfrom observingthatalongourproposed asymp-
totic BGP, gℓ = gs since both st and ℓt are inversely proportional to δt˜ vt —
see (42) above.
7. A number of other growth rates follow in a straightforward way from the var-
ious production functions. Most important of these is the growth rate of At.









t . The exponential de-
cline in st will then crucially distinguish the growth rates of At and Bt, since
1 − st → 1 will be asymptotically constant, while st falls exponentially. There-
fore, taking logs and derivatives of these equations, their asymptotic growth
rates must satisfy
gA =
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8. Combining (44), (45), and (46), gives
g˜ v = (γ − 1)
￿





9. So to get the growth rate of δt˜ vt, we now need an expression for gδ. Recall
δt = (Bα
t (1 − ℓt)(1 − σt))−β. Since 1 − ℓt converges to one while σt → σ∗,
gδ = −αβgB. (48)
10. Now, ﬁnally, look back at (42) and consider the asymptotic growth rate of each
side of the equation. Along our proposed balanced growth path, 1 − st con-
verges to one, so its growth rate converges to zero. The share st falls exponen-
tially, leading the left side to grow, while the right side of the equation grows
as δt˜ vt. Using our last two results in (47) and (48), taking growth rates of (42)
gives
−gs = −αβgB + (γ − 1)
￿





Solving for gs then gives
gs =
−αgB(γ − 1 − β)
1 + (γ − 1)(1 + αλ
1−φ)
. (50)
Under our keyassumption that γ > 1+β,this solution for gs is negative, as we
conjectured earlier.
11. For completeness, one can also solve for σ∗, the share of the population that
becomes scientists. Using (FOC: σ) and making some natural substitutions,
we ﬁnd
σ∗
1 − σ∗ =
αλgB
ρ − gpb − φgB
(51)
where, from (40), gpb = ¯ n−gs + (γ − 1)gc > 0. This means that for the denom-
inator in (51) to be positive, we require
ρ − ¯ n + gs − (γ − 1)gc − φgB > 0, (52)38 CHARLES I. JONES
which, given the solutions for gs, gc, and gB implicitly provides the condition
on ρ needed for utility to be ﬁnite and for this general problem to be well-
deﬁned.
Proof of Proposition 3. Optimal Growth with γ < 1 + β
The ﬁrst part of the proof follows exactly what we did earlier in proving Proposi-
tion 2. In particular, steps 1 through 3 are identical.










If γ ≤ 1, this ratio (the value of a year of life relative to consumption) will
converge to a constant as ct → ∞, whereas if γ > 1, the ratio will grow to
inﬁnity. This turns out not to matter very much in what follows. In particular,
we will focus on the γ > 1 case below, so that
g˜ v = (γ − 1)gc. (53)
(To consider the casewhere γ < 1, simply replace the (γ−1) terms below with
a zero, reﬂecting the appropriate value of g˜ v.)
5. Now we guessthat the solution for the asymptotic balancedgrowth path takes
the following form: ˜ st ≡ 1 − st and ˜ ℓt ≡ 1 − ℓt fall toward zero at a constant
exponential rate, while σt → σ∗ andnt → ¯ n. That is,the allocation ofscientists
and workers shifts away from life and toward the consumption sector.
6. Under this proposed solution, consumption growth is
gc = αgA (54)
while growth of the life-saving aggregate is
gh = αgB + g˜ ℓ = αgB + g˜ s. (55)LIFE AND GROWTH 39
The last inequality comes from noting that g˜ ℓ = g˜ s from step 2 in the proof of
Proposition 2; see the discussion surrounding equation (42) above. In fact, it
is helpful to repeat that equation here, written in terms of the tilde variables:
˜ st
1 − ˜ st
= βδt˜ vt  
ρ − gpat − φgAt





7. A number of other growth rates follow in a straightforward way from the var-
ious production functions. Most important of these is the growth rate of Bt.









t . The exponential de-
cline in ˜ st will then crucially distinguish the growth rates of At and Bt, since
1 − ˜ st → 1 will be asymptotically constant, while ˜ st falls exponentially. There-






λ(¯ n + g˜ s
1 − φ
. (57)
8. Combining (53), (54), and (57), gives
g˜ v = (γ − 1)¯ g. (58)
9. So to get the growth rate of δt˜ vt, we now need an expression for gδ. Recall
δt = (Bα
t ˜ ℓt(1 − σt))−β. Therefore, gδ = −β(αgB + g˜ ℓ). Using this and the fact
that g˜ ℓ = g˜ s gives
gδ = −β
￿





Combining (58) and (59) leads to







10. Now, look back at (56) and consider the asymptotic growth rate of each side of
the equation. Along our proposed balanced growth path, 1 − ˜ st converges to
one, soitsgrowth rateconvergestozero. The share ˜ st fallsexponentially, while
the right side of the equation grows with δt˜ vt. Using our last several results40 CHARLES I. JONES
in (58), (59), and (60) gives







Solving for g˜ s then gives
g˜ s =
−¯ g(β + 1 − γ)
1 + β(1 + αλ
1−φ)
. (62)
Under our keyassumption that γ < 1+β,this solution for g˜ s is negative, as we
conjectured earlier.
11. Substituting this result into (55) then gives the growth rate of the life-saving
aggregate:
g∗
h = ¯ g  
 
1 + (γ − 1)(1 + αλ
1−φ)
1 + β(1 + αλ
1−φ)
!
< ¯ g. (63)
Proof of Proposition 4. Optimal Growth with 1 < γ = 1 + β
The proof here is straightforward and follows from the earlier proofs. For exam-
ple, since γ = 1 + β, one can see from equation (50) that gs = 0. The key growth
rates of the economy are then equal to ¯ g immediately.
B Data Appendix
This appendix describes the construction of the data on the fraction of R&D expen-
ditures associated with health. Two separate efforts are made, one using U.S. data
and the other using OECD data. These are discussed in turn.
B1. United States
Several main sources are used to construct the US data underlying Figure 2. A
spreadsheetavailablefromthedatasectionofmywebpagecalledNSF-AllYears-IndustrialRND.xls
contains the detailed calculations.
First, for the years 1971 to 1993, various issues of the NIH Data Book report a
time series for the key variable in which we are interested: the fraction of R&D re-LIFE AND GROWTH 41
lated to health. In particular, we use the NIH Data Books for 1982, 1989, and 1994,
splicing together these series during overlapping years to construct our ﬁrst mea-
sure of health R&D. Unfortunately, these data do not appear to be available online,
so I used physical copies of the data books.
Our other measures are obtained from a more involved calculation using the
following sources:
• Centers for Medicare and Medicaid Services, National Health Expenditure Ac-
counts, 1960–2009. This data source provides an extensive account of health
expenditures, including a “research” category. However, because the purpose
is to provide an accounting of health expenditures, the research category only
includes non-commercial research. As stated on page 26 of National Health
Expenditure Accounts: Deﬁnitions, Sources, and Methods 2009,
Research shown separately in the NHEA is that of non-proﬁt or gov-
ernment entities. Research and development expenditures by drug
and medical supply and equipment manufacturers are not shown
in this line, as those expenditures are treated as intermediate pur-
chases under the deﬁnitions of national income accounting; that is,
thevalueofthatresearchisdeemedtoberecoupedthrough product
sales.
• National Science Foundation IRIS data, 1953–1998, Table H-25. From this
source, we obtain “Company and other (except Federal) funds for industrial
R&D performance, by industry” for 1953–1998. In particular, we sum three in-
dustries to get commercial health research: “drugs and medicines” (SIC 283),
“health services” (SIC 80), and then a fraction of “optical, surgical, photo-
graphic, and other instruments” (SIC 384-387). This fraction is equal to 0.569,
whichis obtained byusingthe averageratio ofhealthR&Don“medicalequip-
ment and supplies” for 1997 and 1998 (the two overlapping years) from our
next source.
• National Science Foundation, Research and Development in Industry, vari-
ous issues (2000, 2002, 2003, 2004, 2005). This source reports “Company and42 CHARLES I. JONES
other nonfederal funds for industrial R&D performance” for various years us-
ing theNAICSindustry classiﬁcation. We sumthree industries togetcommer-
cial health research: Pharmaceuticals and medicines (3254), Medical equip-
mentandsupplies (3391), andHealthcare services(621-623). RaymondWolfe
kindly provided the 2006 and 2007 versions of this data.
• Finally, total spending on R&Dis obtained from the National Science Founda-
tions, National Patterns of R&D Resources: 2008 Data Update, which reports
data for 1953–2008.
Notice that our measures of commericial/industry R&D exclude federal funds
but do include non-proﬁt or state and local funding for R&D. This may result in
some double counting. The comparison of the NIH Data Book numbers to those
that I construct from the NSF sources suggests that this is not a large problem —
see Figure 2 in the paper.
B2. OECD
The OECD (and US) data underlying Figure 3 are taken from the OECD iLibrary. A
spreadsheetavailablefromthedatasectionofmywebpagecalledSTAN-HealthRND.xls
contains the detailed calculations.
Two sets of data from the OECD iLibrary are used:
• Government budget appropriations or outlays for RD: This source provides
government spending on R&Dfor health and overall from 1981 to 2007 in cur-
rent PPP-adjusted US dollars.
• STAN R&DExpenditure in Industry (ISICRev. 3) ANBERDed2009: This source
provides spendingonR&Dbyindustry. Becauseofarelativelylimitedindustry
breakdown, our health measure is the sum of spending in the pharmaceutical
industry (C2423) and 0.5 times the spending in the “medical, precision and
optical instruments” industry (C33); this weight of 0.5 is obviously arbitary
but was suggested by calculations using the U.S. sources discussed earlier.
From this data, we calculate the health share of R&D for both the United States
and for a set of OECD countries. For government R&D, our OECD aggregate in-LIFE AND GROWTH 43
cludes the United States, the United Kingdom, France, Germany, Italy, Japan, and
Canada. For some reason, the industry data for France and the United Kingdom are
not available, so these countries are not included in the industry component.
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